Related references
Note: Only part of the references are listed.VKORC1 mutations in patients with partial resistance to phenprocoumon
Peter C. J. Schmeits et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Structure of a bacterial homologue of vitamin K epoxide reductase
Weikai Li et al.
NATURE (2010)
Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners
Sol Schulman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Novel mutations in the VKORC1 gene of wild rats and mice - a response to 50 years of selection pressure by warfarin?
Simone Rost et al.
BMC GENETICS (2009)
A new VKORC1 mutation leading to an isolated resistance to fluindione
Katell Peoc'h et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience
Thomas P. Moyer et al.
MAYO CLINIC PROCEEDINGS (2009)
Warfarin pharmacogenetics:: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
Stuart A. Scott et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
Eleni Aklillu et al.
BLOOD (2008)
A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance
F. N. Ainle et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2008)
A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon
E. B. Wilms et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1
D. J. Harrington et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans
L. Bodin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon
Yvonne van Leeuwen et al.
THROMBOSIS RESEARCH (2008)
Biochemistry of resistance to warfarin in a French strain of the Norway rat (Rattus norvegicus)
R. Lasseur et al.
INTERNATIONAL JOURNAL OF PEST MANAGEMENT (2007)
VKORC1:: molecular target of coumarins
J. Oldenburg et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines
Da-Yun Jin et al.
BIOCHEMISTRY (2007)
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Ronen Loebstein et al.
BLOOD (2007)
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status:: interaction between both genotypes affects dose requirement
T. Schalekamp et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme
R. L. D'Ambrosio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2
Pei-Hsuan Chu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population:: a retrospective analysis of case records
A. Osman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Vitamin K epoxide reductase complex subunit 1 (VKORC1):: The key protein of the vitamin K cycle
Johannes Oldenburg et al.
ANTIOXIDANTS & REDOX SIGNALING (2006)
Heterogeneity of the coumarin anticoagulant targeted vitamin K epoxide reduction system. Study of kinetic parameters in susceptible and resistant mice (Mus musculus domesticus)
Romain Lasseur et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2006)
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance
L Bodin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation
JK Tie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients:: A HuGEnet™ systematic review and meta-analysis
S Sanderson et al.
GENETICS IN MEDICINE (2005)
Warfarin resistance in a French strain of rats
R Lasseur et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
F Kamali et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Identification of the gene for vitamin K epoxide reductase
T Li et al.
NATURE (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Evaluation of a warfarin initiation protocol for older people
TJ Wilkinson et al.
INTERNAL MEDICINE JOURNAL (2003)
Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16
A Fregin et al.
BLOOD (2002)
Share Paper
